Publications by the researcher in collaboration with Manuel Barreiro de Acosta (24)
2024
-
Efficacy and safety of biological treatment for inflammatory bowel disease in elderly patients: Results from a GETECCU cohort
Gastroenterologia y Hepatologia
-
Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA
Clinical Gastroenterology and Hepatology
-
Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA
Pharmaceutics, Vol. 16, Núm. 5
2023
-
Benefits of Paediatric to Adult Transition Programme in Inflammatory Bowel Disease: The BUTTERFLY Study of GETECCU and SEGHNP
Journal of Clinical Medicine, Vol. 12, Núm. 14
-
Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry
Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91
-
Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated with Internal Fistulizing Disease: BIOSCOPE Study from GETECCU
American Journal of Gastroenterology, Vol. 118, Núm. 6, pp. 1036-1046
2022
-
Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)
Journal of Clinical Medicine
-
Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study
Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736
-
Psychosocial impact of the COVID-19 pandemic on patients with inflammatory bowel disease in Spain. A post lockdown reflection
Gastroenterologia y Hepatologia, Vol. 45, Núm. 9, pp. 668-676
-
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
Journal of Clinical Medicine, Vol. 11, Núm. 24
-
Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab
Journal of Clinical Medicine, Vol. 11, Núm. 15
2021
-
Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry
Journal of Crohn's and Colitis, Vol. 15, Núm. 11, pp. 1846-1851
2019
-
Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial
Therapeutic Advances in Gastroenterology, Vol. 12
-
Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU
Alimentary Pharmacology and Therapeutics, Vol. 49, Núm. 4, pp. 419-428
2016
-
Urine metabolome profiling of immune-mediated inflammatory diseases
BMC Medicine, Vol. 14, Núm. 1
2015
-
Clinical, biological, and endoscopic responses to adalimumab in antitumor necrosis factor-naive Crohn's disease: Predictors of efficacy in clinical practice
European Journal of Gastroenterology and Hepatology, Vol. 27, Núm. 4, pp. 430-435
2014
-
Drug trough levels and primary nonresponse to antiTNF therapy in moderate-severe Crohn disease
Gastroenterology, Vol. 146, Núm. Suppl. 1, pp. 247
2013
-
Increasing incidence of pediatric inflammatory bowel disease in Spain (1996-2009): The SPIRIT registry
Inflammatory Bowel Diseases, Vol. 19, Núm. 1, pp. 73-80
2012
-
Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: A multicentre study
Alimentary Pharmacology and Therapeutics, Vol. 35, Núm. 2, pp. 275-283
2011
-
Pharmacogenetics study of TPMT and ITPA genes in patients with inflammatory bowel disease treated with azathioprine detects relation between ITPase deficiency and clinical response
Journal of Crohns & Colitis, Vol. 5, Núm. 1, pp. S162-S161